

Title page

Baseline Characteristics and Outcomes of 180 Egyptian COVID-19 Patients Admitted to Quarantine Hospitals of Ain Shams University: A Retrospective Comparative Study

Running title: COVID-19 in Egypt

Sara I. Taha ^{a*}, Sara F. Samaan ^b, Aalaa K. Shata ^c, Shereen A. Baioumy ^d,
Shaimaa A. Abdalgeleel ^e, Mariam K. Youssef ^a

^a Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

^b Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

^c Department of Pulmonary Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

^d Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Egypt.

^e Department of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt

Authors:

***Sara Ibrahim Taha, M.D., Ph.D.**

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

E-mail: dr_sara_ib@med.asu.edu.eg ORCID: <https://orcid.org/0000-0001-8224-8701>

Sara Farid Samaan, M.D., Ph.D.

Lecturer of Internal Medicine/ Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

E-mail: Dr.sara_farid@yahoo.com

Aalaa Kamal Shata, M.D., Ph.D.

Lecturer of Pulmonary Medicine, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

E-mail: aalaashata@yahoo.com

Shereen Atef Baioumy, M.D., Ph.D.

Lecturer of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Email: drshereenatef@yahoo.com ORCID: <https://orcid.org/0000-0002-2188-6790>

Shaimaa Abdalaleem Abdalgeleel, M.D., Ph.D.

Lecturer of Biostatistics and Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt.

E-mail: shaimaa.abdalgeleel@nci.cu.edu.eg ORCID: <https://orcid.org/0000-0003-0994-7703>

Mariam Karam Youssef, M.D., Ph.D.

Lecturer of Clinical Pathology/Hematology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.

E-mail: Dr.mariam_karam@hotmail.com ORCID: <https://orcid.org/0000-0003-2075-3889>

* Corresponding Author:

Sara Ibrahim Taha, MD, PhD

Lecturer of Clinical Pathology/ Immunology, Faculty of Medicine, Ain Shams University.

Address: Ain Shams University, Abassia, Cairo, Egypt

Office tel., fax: + (202) 24346308 Mobile: + (20) 1125360009

E-mail: dr_sara_ib@med.asu.edu.eg

<https://orcid.org/0000-0001-8224-8701>

1 **Abstract:**

2 **Background:** COVID-19 mortality, severity, and recovery are major global concerns, but they
3 are still insufficiently understood, particularly in the Middle East. **Methods:** This retrospective
4 study comprised 180 adult Egyptian COVID-19 patients who were categorized and compared to
5 evaluate if there was a link between their clinical and laboratory findings at hospital admission
6 and disease severity and mortality risk. **Results:** Of all patients enrolled, 27.8% had severe
7 disease and 13.9% died during their hospital stay. Diabetes mellitus (46.7%), hypertension
8 (36.1%) and chronic obstructive pulmonary disease (COPD) (33.3%) were the most frequent
9 associated co-morbidities. Severe patients and non-survivors were significantly older compared
10 to their corresponding groups. Their absolute neutrophil count, procalcitonin (PCT), ESR, C-
11 reactive protein (CRP), AST, ALT, LDH, D-dimer, and ferritin levels were all significantly
12 higher ($P \leq 0.05$), whereas their absolute lymphocyte count was significantly lower ($P \leq 0.05$).
13 COPD (OR: 3.294; 95% CI: 1.199-9.053; $P= 0.021$), diabetes mellitus (OR: 2.951; 95%
14 CI:1.070-8.137; $P= 0.037$), ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551; $P= 0.001$),
15 AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991; $P= 0.021$), CT-SS ≥ 17 (OR: 1.205; 95% CI:
16 1.089-1.334; $P \leq 0.001$) and absolute lymphocyte count $< 1 \times 10^3/\mu\text{L}$ (OR: 4.002; 95% CI: 1.537-
17 10.421; $P= 0.005$), were all linked to a higher risk of COVID-19 severity. Furthermore, COVID-
18 19 in-hospital mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359; $P= 0.043$),
19 CT-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482; $P= 0.002$) and AST ≥ 40 IU/L (OR: 2.89; 95%
20 CI: 1.091-7.661; $P= 0.033$). **Conclusions:** Clinical and laboratory data of COVID-19 patients at
21 their hospital admission may aid in identifying early risk factors for severe illness and a high
22 mortality rate, as well as determining the most effective management for them.

23 **Keywords:** Coronavirus; COVID-19; Egypt; Indicators; Mortality; Severity.

25 **INTRODUCTION:**

26 Coronavirus disease 2019 (COVID-19) is a highly contagious infection caused by the severe
27 acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that was first discovered in Wuhan,
28 China, in early December 2019. Since then, the disease has rapidly spread to become a global
29 epidemic [1]. The first COVID-19 case in Egypt was reported in February 2020, and since then,
30 the number of cases has been dramatically rising. According to the Egyptian Ministry of Health
31 and Population, there were more than 266,000 confirmed COVID-19 cases and almost 15,200
32 COVID-19 deaths throughout Egypt and its governorates as of June 5, 2021 [2].

33 COVID-19 infection is most commonly transmitted through respiratory droplets, as well as
34 human-to-human contact [3]. It causes a wide range of symptoms that can lead to patient
35 mortality, making it difficult to treat and control [4]. It also depletes hospital resources, such as
36 ICU beds and mechanical ventilators, especially in low-resource countries [5]. So far, no specific
37 antiviral therapy for COVID-19 has been found to be effective, and clinical management is based
38 primarily on symptom control [6]. Several vaccinations began to emerge toward the end of 2020.
39 According to the World Health Organization (WHO), there were 102 vaccines in clinical trials
40 and 184 vaccines in preclinical trials as of May 28, 2021 [7].

41 The goal of this study was to understand more about COVID-19 baseline features and outcomes
42 in Egyptian patients, which could aid in detecting early risk factors for poor prognosis and
43 guiding proper patient management.

44 **METHODOLOGY:**

45 **Study subjects and settings**

46 This retrospective study included 180 COVID-19 adult patients (age \geq 18 years old) admitted
47 from March 1 to April 30, 2021 to the Quarantine Hospitals of Ain-Shams University (El-
48 demerdash hospital and Field hospital), Cairo, Egypt. Only confirmed SARS-CoV-2 cases
49 through nasopharyngeal swabs real-time reverse-transcriptase–polymerase-chain-reaction (RT–
50 PCR) assays, in accordance with WHO guidance [8], were enrolled in the study. Pregnant
51 women, patients with missing data and those who had hematological diseases or immunological
52 disorders were excluded from the study.

53 **Data collection:**

54 Baseline data including: age, gender, presenting symptoms, comorbidities and chronic diseases,
55 chest computed tomography (CT), ICU admission necessity, length of hospital stay and outcome
56 (survival or non-survival), as well as baseline routine laboratory test results (CBC with
57 differential counts, CRP, ESR, ferritin, D-dimer, PCT, LDH, AST and ALT) were acquired from
58 medical records of all included patients.

59 Before the start, The Ain Shams University Faculty of Medicine Research Ethics Committee
60 (REC) gave its permission for the study to be carried out. Informed consent was waived due to
61 the retrospective nature of this study. Data were collected from hospital records in an anonymous
62 pattern, kept private and confidential. They were solely utilized for the purpose of research.

63 **Patient categorization:**

64 All included patients were categorized according to guidelines of the management protocol of
65 COVID-19 patients released by Ain Shams University Hospitals [9]. Patients were considered to
66 have severe/critical disease if one or more of the following were present: oxygen saturation \leq
67 93% at rest; dyspnea with a respiratory rate \geq 30 breath/min; arterial partial oxygen pressure

68 (PaO₂)/fraction of inspired oxygen (FiO₂) ≤ 300 mmHg; respiratory failure with a need for
69 mechanical ventilation; ICU admission need with shock, or organ failure syndrome. COVID-19
70 patients who did not meet these criteria but had a positive COVID-19 nucleic acid test were
71 classified as having mild to moderate disease severity (non-severe).

72 **Calculation of CT scoring system:**

73 Each of the five lung lobes was visually assessed for the extent of involvement, whether
74 unilateral or bilateral; peripheral, central, or both; upper lobe predominance, lower lobe
75 predominance, or both; and then graded on a scale of 0 to 5 (degree of involvement: 0%, less
76 than 5%, 5–25%, 26–49%, 50–75%, and > 75%, respectively). The sum of the individual lobar
77 grades was then used to create a score that ranged from 0 to 25 [10,11].

78 **Statistical methods:**

79 The results were generated using the Statistical Package of Social Science (SPSS) (version 26).
80 Quantitative numerical data were described as means and standard deviations (SD) or medians
81 and ranges. While qualitative data were described as frequencies and percentages. Comparisons
82 were done using the Mann-Whitney –U test or the Chi-square test or Fisher’s exact test as
83 appropriate. The significant variables in the univariate analysis were subjected to stepwise
84 logistic regression, and the odds ratio (OR) and its 95% confidence intervals (CI) were calculated
85 to estimate the risk. Probability (p-value) ≤ 0.05 was considered significant.

86 **RESULTS:**

87 **Demographics and associated co-morbidities:**

88 A total of 180 COVID-19 patients were enrolled in this study. Their median (IQR) age was 48
89 years (15-94). Thirty five percent of the patients were males and 65% were females. The most
90 common associated co-morbidities were diabetes mellitus (46.7%), hypertension (36.1%) and
91 chronic obstructive pulmonary disease (COPD) (33.3%). Of all the studied population, 27.8%
92 (n=50) had severe disease and 13.9% (n=25) died during their hospital stay. Patients of these 2
93 subgroups were significantly older compared to non-severe patients (median: 60 years (IQR:22-
94 91) vs. 43 years (15-94); P=0.004) and survivors (57.0 years (27-80) vs 45.0 years (15-94);
95 P=0.005), respectively. In terms of sex, differences between the studied subgroups were not
96 significant. Demographics and associated co-morbidities are shown in **Table 1**.

97 **Baseline clinical characteristics and patients' outcomes:**

98 **Table 2** shows baseline clinical characteristics and outcomes of all studied patients and
99 according to COVID-19 severity and mortality. The most frequent symptoms at admission were
100 fatigue (90.6%), myalgia (75.0%), arthralgia (73.9%), fever (69.4%), dyspnea (69.4%) and
101 cough (68.9%). Only dyspnea was significantly associated with COVID-19 in-hospital mortality
102 (88.0% vs. 66.5%; P= 0.030). Patients with severe COVID-19 had significantly higher rates of
103 thrombotic manifestations (38.0% vs. 22.3%; P=0.030), but no significant difference between
104 non-survivors and survivors was found (36.0% vs. 25.2%; P=0.255). Regarding CT-SS,
105 significantly higher scores were observed in severe patients (median: 21 (IQR: 5-23) vs. 15 (0-
106 24); $P \leq 0.001$) and non-survivors (20 (0-24) vs. 7 (0-23); $P \leq 0.001$) compared to their
107 corresponding groups.

108 In the 180 patients, the ICU admission rate was 30.6% with significant higher rates in severe
109 patients and non-survivors compared to non-severe patients (96.0% vs. 5.4%; $P \leq 0.001$) and
110 survivors (80.0% vs. 22.6%; $P \leq 0.001$). In hospital mortality rates were significantly higher with

111 severe compared to non-severe disease (32.0% vs. 6.9%; $P \leq 0.001$). The median (IQR) duration
112 of hospital stay of all studied patients was 14 days (3-29), with significant longer durations in
113 severe patients (22 days (10-29) vs. 10 days (3-22); $P \leq 0.001$) and non-survivors (22 days (3-29)
114 vs. 12 days (3-29); $P=0.001$) compared to their corresponding groups.

115 **Laboratory findings:**

116 Those with severe disease and non-survivors exhibited significantly higher ($P \leq 0.05$)
117 coagulation function (D-dimer), inflammation (PCT, ESR, CRP, and ferritin), liver dysfunction
118 (AST and ALT), and tissue damage (LDH) compared to their corresponding groups. On the other
119 hand, their CBCs showed significantly lower absolute lymphocyte counts ($P \leq 0.05$) with
120 significantly higher absolute neutrophil counts ($P \leq 0.05$). There were no significant differences
121 ($P > 0.05$) in hemoglobin level, total leukocyte and platelet counts between the studied
122 categories. **Table 3** shows the biochemical and hematological characteristics of the included
123 patients.

124 **Indicators of COVID-19 severity and in-hospital mortality:**

125 In **table 4**, multivariate logistic regression analysis was used to identify independent prognosis
126 indicators associated with COVID-19 severity and in-hospital mortality. Predictors of COVID-
127 19 severity in the studied patients were presence of COPD (OR: 3.294; 95% CI: 1.199-9.053; $P=$
128 0.021) and diabetes mellitus (OR: 2.951; 95% CI:1.070-8.137; $P= 0.037$) as co-morbidities,
129 abnormal high values of ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551; $P= 0.001$),
130 AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991; $P= 0.021$) and CT-SS ≥ 17 (OR: 1.205; 95%
131 CI: 1.089-1.334; $P \leq 0.001$), as well as low absolute lymphocyte count $< 1 \times 10^3/\mu\text{L}$ (OR: 4.002;
132 95% CI: 1.537-10.421; $P= 0.005$). The presence of dyspnea as a presenting symptom (OR:

133 4.006; 95% CI: 1.045-15.359; P= 0.043), CT-SS \geq 17 (OR: 1.271; 95% CI: 1.091-1.482; P=
134 0.002) and AST \geq 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661; P= 0.033) were also found to be
135 independent predictors of COVID-19 in-hospital mortality.

136 **DISCUSSION:**

137 In the current study, comprehensive data analysis on the demographic, clinical, laboratory and
138 radiological characteristics and outcomes of 180 hospitalized adult Egyptian COVID-19 patients
139 were presented. The non-severe cases of COVID-19 (72.2%), as well as the survivors (86.1%),
140 were by far the most prevalent in this study.

141 This study revealed that the severity and mortality of COVID-19 were significantly predominant
142 in the older age groups. This could be explained by the age-dependent decline in cell-mediated
143 and humoral immune functions, resulting from low-grade chronic inflammation [12], as well as
144 the increased risk of multi-organ failure in elderly individuals due to their lower ability to correct
145 for hypoxia [13]. In agreement with our findings, several studies reported that elderly patients
146 with COVID-19 are more likely to progress to severe disease with worse outcomes, compared to
147 young and middle-aged patients [14-16]. In contrast, Wang and colleagues couldn't link COVID-
148 19 severity or mortality to a certain age group [17].

149 According to several studies, COVID-19 has infected more males than females, [18,19]. Female
150 gender may be a protective factor, as evidenced by the fact that women have fewer harmful
151 habits than men, particularly smoking [20]. Females may also have stronger innate and adaptive
152 immune responses than males, making them more resistant to infections [21]. In terms of
153 COVID-19 severity and mortality, our research found no significant differences between male
154 and female patients. Wang et al. and Fois et al., like us, discovered no gender differences in
155 disease severity or mortality [12,22].

156 Diabetes mellitus, hypertension, and COPD were the most common chronic disorders among
157 COVID-19 participants in our study. These co-morbidities were found to be strongly linked to
158 disease progression. In addition, the odds of COVID-19 severity were 3.294 and 2.951 folds
159 greater in COPD and diabetic patients, respectively. These findings were in line with a meta-
160 analysis research that found diabetes mellitus and hypertension to be of the most common
161 underlying disorders among COVID-19 patients who were hospitalized [23]. Consistent with our
162 findings, Marhl et al. found a greater risk of COVID-19 in diabetic individuals due to the related
163 dysregulation of angiotensin-converting enzyme-2 (ACE-2), liver dysfunction, and chronic
164 inflammation [24]. In addition, the elevated risk of COVID-19 infection in patients with pre-
165 existing cardiovascular illness may be due to a decrease in pro-inflammatory cytokines, which
166 leads to weakened immune function [25]. In previous studies on MERS-CoV-2, it was
167 discovered that the virus's particular receptor, dipeptidyl peptidase-4, was expressed at a higher
168 level in smokers and COPD patients [26]. Emami et al. suggested that COPD could be an
169 underlying factor that makes patients more prone to COVID-19 development [23], which is
170 similar to our findings. Zhang et al., on the other hand, were unable to relate COVID-19 to
171 COPD [27].

172 The most common symptoms found at admission of our COVID-19 patients were; fatigue
173 (90.6%), myalgia (75%), arthralgia (74%), fever (69.4%), dyspnea (69.4%), and cough (68.9%).
174 In accordance to our results, Ghweli and co-workers found that malaise, fever, dry cough, and
175 dyspnea, were the most common manifestations of COVID-19 [14]. Dyspnea was found to be a
176 significant prominent feature among the non-survivors in this study. Furthermore, the risk of
177 disease mortality was 4.006 times higher in patients who presented with dyspnea than in those
178 who did not. Similarly, Zheng et al. reported a significant positive association of dyspnea with

179 COVID-19 progression to death [28]. Also, a meta-analysis study reported similar findings and
180 recommended dyspnea rather than fever as an indicator of poor outcome in COVID-19 patients
181 [29].

182 Individuals with COVID-19 may have coagulation abnormalities, promoting a hypercoagulable
183 state and resulting in an increased rate of thrombotic and thromboembolic events [30]. Using
184 whole blood thromboelastography, Panigada et al. identified hypercoagulability features in
185 COVID-19 patients, such as a decrease in time to fibrin formation, a decrease in time to clot
186 formation, and an increase in clot strength [31]. In the context of these findings, a significant
187 proportion of severe patients in our study were presented with thrombotic manifestations at
188 admission to the hospital.

189 Severe patients tend to get priority hospitalization, with an increased need for oxygen
190 supplementation, intensive care, and even mechanical ventilation [18]. Similarly, in our study,
191 the length of hospital stay and the necessity for ICU admission were both considerably higher in
192 severe patients and non-survivors.

193 Regarding complete blood count in COVID-19, peripheral blood leukocyte and lymphocyte
194 counts are found to be normal or slightly reduced during the early phase of the disease, when
195 non-specific symptoms are present. Approximately 1 to 2 weeks from the onset of the initial
196 symptoms, when there is a surge in the clinical manifestations of the disease coinciding with a
197 pronounced systemic increase of inflammatory mediators and cytokines, significant lymphopenia
198 becomes evident [32]. Several factors may contribute to COVID-19-associated lymphopenia: the
199 virus may directly infect lymphocytes, resulting in their lysis; the markedly increased levels of
200 interleukins may promote lymphocyte apoptosis; the cytokine storm may be associated with
201 lymphoid organ atrophy; and the metabolic acidosis present in severe COVID-19 patients may

202 suppress the proliferation of lymphocytes [32]. On the other hand, neutrophils are triggered by
203 virus-related inflammatory factors produced by lymphocytes and endothelial cells, releasing
204 large amounts of reactive oxygen species, neutrophil extracellular traps, and other cytotoxic
205 mediators, which may dampen the virus [33]. Also, platelets may have an important role in the
206 regulation of virus-mediated inflammatory process [34]. The platelet count of most mild to
207 moderate COVID19 patients may be normal or elevated but it may be reduced in critically ill
208 patients. In individuals with severe COVID19, thrombocytopenia may be caused by a decrease in
209 platelet production, an increase in platelet breakdown, or a decrease in circulating platelets [35].
210 In the current study, the hematological indices of the included COVID-19 patients revealed
211 significantly lower median absolute lymphocyte counts and higher median absolute neutrophil
212 counts; yet without neutrophilia, among severe patients and non-survivors. Also, lymphopenia <
213 $1 \times 10^3/\mu\text{L}$ was an independent predictor of disease severity (OR: 4.002). However, total
214 leukocytic count, hemoglobin level, and platelet counts showed no significant differences as the
215 disease progressed. In accordance to our results, lymphopenia has been recognized in many
216 studies as an effective and reliable indicator of severity and mortality in COVID-19 patients
217 [14,18,36]. Also, many studies reported that non-survivors presented with significantly higher
218 neutrophil counts [4,36,37]. Moreover, Shang et al. found that hemoglobin levels were not
219 influenced by the severity of the disease [38]. As opposed to our findings, Li et al. have found
220 significant leucopenia and thrombocytopenia in the severe patients [18]. In addition, Sulejmani et
221 al. reported significant leukocytosis in severe COVID-19 patients, which could be related to the
222 hyper-inflammatory state [39].
223 It has been reported that viral infection could induce an acute systemic inflammatory syndrome
224 characterized by fever and multiple organ dysfunction. Additionally, viral infection induces

225 acute phase reactant production [40]. CRP is an inflammatory marker that plays an important
226 role in host resistance to invading pathogens. Higher CRP values have been linked to several
227 unfavorable aspects of COVID-19 including, cardiac injury, respiratory distress, and death. The
228 detection of CRP levels was reported to be of great value in assessing the severity of COVID-19
229 patients [4]. Binding and storage of iron, which are functions of ferritin, are also associated with
230 immune and inflammatory response to viral infection [41]. Procalcitonin (PCT) has been
231 recently suggested as a valuable inflammatory prognostic biomarker in identifying COVID-19
232 patients at high risk for clinical deterioration [42]. Our findings revealed significantly higher
233 inflammatory and tissue damage markers (CRP, ESR, ferritin, PCT, and LDH) among severe
234 COVID-19 patients and those who died from the disease. Also, ferritin ≥ 350 ng/mL was an
235 independent predictor of COVID-19 severity with an odds ratio of 11.08. These findings were in
236 agreement with several other studies [4,18,41,42].

237 Coagulation disorders are relatively frequently encountered among severe COVID-19 patients.
238 The D-dimer dynamics can reflect disease severity and elevated D-dimer level is associated with
239 adverse patients' outcomes [14,30]. In accordance, D-dimer levels in our studied patients
240 increased significantly as the disease worsened.

241 One of the mechanisms by which COVID-19 can invade the human body is by binding to human
242 ACE-2 receptor with subsequent enhancement of ACE-2 expression in hepatocytes [43]. Chen et
243 al. discovered a slight increase in ALT and AST serum values in 43.4% of COVID-19 cases
244 from Wuhan, which was the first report of hepatic dysfunction in SARS-CoV-2 infection [36]. A
245 link between aberrant liver biochemistry and COVID-19 severity has recently been discovered
246 [18]. In a study in Shanghai, severe to critical cases exhibited significantly higher serum ALT
247 and AST levels than those who had mild to moderate COVID-19 [44]. In line with these

248 findings, the present study revealed significantly higher serum values of both ALT and AST
249 among severely infected COVID-19 patients and those who died from the disease. In addition,
250 $AST \geq 40$ IU/L was an independent predictor of COVID-19 severity and mortality with an odds
251 ratio of 3.076 and 2.890, respectively.

252 The use of CT imaging for the diagnosis and grading of viral pneumonia, allows patients with
253 suspected SARS-CoV-2 infection to be isolated and treated in time for recovery, thus optimizing
254 patient management [45]. Ground-glass opacities, consolidations and Broncho vascular
255 thickening are characteristic chest CT findings in COVID-19 pneumonia. Atypical chest CT
256 features also include masses, nodules, cavitation, lymphadenopathy, and pleural effusion [46].
257 The CT-scoring system (CT-SS), which has a high predictive value for the dynamic changes in
258 chest CT exams in different severities of COVID-19 pneumonia [46], can be used to assess the
259 extent of lung involvement. Both lungs were divided into 12 zones in total in the scoring
260 methodology of Zhou et al; the degree of involvement in each lung zone was scored from 0 to 4,
261 with a maximum achievable score of 48 [47]. Yang and coworkers developed another scoring
262 system in which both lungs were divided into 20 zones and examined on chest CT using a
263 methodology that assigned scores of 0, 1, and 2; hence, the individual's total score may vary
264 from 0 to 40 points [48]. In this current study, the lung lobar involvement scoring system (0–25)
265 was used as it was practical and time-effective [10,11,46], and showed significantly higher
266 scores in the severe and non-survivor patients. Moreover, the odds of disease severity and
267 mortality were 1.205 and 1.271 folds higher with CT-SS of ≥ 17 , respectively. In accordance to
268 our findings, in a study by Hafez et al., CT-SS 18/24 was considered the cutoff value among the
269 mild and severe cases [46]. Also, Francone et al. have stated that CT-SS of ≥ 18 is highly
270 predictive of COVID-19 mortality [10].

271 This study has some limitations that should be considered. First, it is a retrospective study that
272 was performed in a limited hospital setting and included a relatively small sample size with
273 disproportion in the different study groups. A large multi-center prospective observational study
274 would be better to authenticate our findings. Another limitation is that all data included in this
275 study were from the official records of the hospital; meanwhile, some patients have not been
276 hospitalized for treatment because of the lack of awareness of disease severity, as well as the
277 shortage of health care facilities. A larger study that includes out-patients isolated at home in
278 addition to hospitalized in-patients, would offer a more representative study population.

279 **CONCLUSIONS:**

280 According to this study, COVID-19 infection was more aggressive in the elderly, diabetic,
281 hypertensive, and COPD patients, as well as in those with low lymphocyte counts, high
282 neutrophil counts, and high CRP, ESR, PCT, LDH, D-dimer, ferritin, AST, and ALT levels at
283 the time of their admission to hospital. Hence, pretreatment clinical and laboratory data from
284 COVID-19 patients at hospital admission may aid in identifying early risk factors for disease
285 progression, as well as determining the most effective management plan.

286 **Abbreviations:**

287 *ACE-2: Angiotensin-converting enzyme-2; COPD: Chronic obstructive pulmonary disease;*
288 *COVID-19: Coronavirus disease 2019; CT-SS: CT-scoring system; RT- PCR: Reverse*
289 *transcription-polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome*
290 *corona virus 2; WHO: World Health Organization.*

291 **Manuscript word count:** 3290 words

292 **Abstract word count:** 285 words

293 **Tables:** 4

294 **Figures:** 0

295 **Data availability statement:** Data will be available upon request.

296 **Acknowledgement:** None.

297 **Conflicts of interest disclosure:** None.

298 **Funding sources:** None

299 **Consent for publication:** Not applicable.

300 **Authors contribution:**

301 *Sara I. Taha*: conceptualization, methodology, writing- reviewing and editing; *Sara F. Samaan*
302 *and Aalaa K. Shata*: data curation, investigation; *Shereen A. Baioumy*; project visualization,
303 resources, software, validation; *Shaimaa A. Abdalgeleel*: formal analysis, supervision; *Mariam*
304 *K. Youssef*: writing-original draft preparation, project administration.

305 **REFERENCES:**

306 [1] Balkhair AA. COVID-19 pandemic: a new chapter in the history of infectious diseases.
307 Oman Med J; 202035(2): e123. DOI: 10.5001/omj.2020.41. PMID: 32328297; PMCID:
308 PMC7171815.

309 [2] Egyptian Ministry of Health. <https://www.care.gov.eg/EgyptCare/Index.aspx>. Accessed
310 5 June, 2021.

311 [3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in
312 Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Mar
313 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. PMID:31995857; PMCID:
314 PMC7121484.

- 315 [4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
316 with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020 Feb 15;395(10223):497-506.
317 doi: 10.1016/S0140-6736(20)30183-5. PMID: 31986264; PMCID: PMC7159299
- 318 [5] Heo, J., Han, D., Kim, HJ, Kim D, Lee YK, Lim D, et al. Prediction of patients requiring
319 intensive care for COVID-19: development and validation of an integer-based score
320 using data from Centers for Disease Control and Prevention of South Korea. *J Intensive*
321 *Care*. 2021 Jan 29;9(1):16. doi: 10.1186/s40560-021-00527-x. PMID: 33514443 PMCID:
322 PMC7844778.
- 323 [6] Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an
324 indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. *J*
325 *Transl Med*. 2020 Oct 29;18(1):406. doi: 10.1186/s12967-020-02571-x. PMID:
326 33121497; PMCID: PMC7594951.
- 327 [7] World Health Organization. DRAFT landscape and tracker of COVID-19 candidate
328 vaccines. who.int. Update May 28, 2021. Accessed May 30,
329 2021. [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
330 [vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines).
- 331 [8] WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human
332 cases, interim guidance. 2020. p. 1–7. Available from: [https://www.who.int/publications-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-sus-pected-human-cases-20200117)
333 [detail/laboratory-testing-for-2019-novel-coronavirus-in-sus-pected-human-cases-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-sus-pected-human-cases-20200117)
334 [20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-sus-pected-human-cases-20200117).
- 335 [9] Abdelfattah E, Ahmed S, El-Zahapy H, EL Said A, Salem S, Tharwat A, et al., Hospital
336 response to COVID-19 a consensus: Report on Ain Shams University Hospital Strategy.

- 337 [published online ahead of print, June 12, 2020]. ScienceOpen. doi:
338 <https://doi.org/10.14293/S2199-1006.1.SOR-.PPD4QZX.v1>
- 339 [10] Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L et al. Chest CT score in
340 COVID-19 patients: correlation with disease severity and short-term prognosis. Eur
341 Radiol. 2020; 4:1 – 10
- 342 [11] Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at Chest
343 CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020;
344 295:715 –721.
- 345 [12] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
346 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
347 China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum
348 in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID: PMC7042881.
- 349 [13] Zou Z, Yang Y, Chen J, Xin S, Zhang W, Zhou X, et al. Prognostic factors for severe
350 acute respiratory syndrome: a clinical analysis of 165 cases. Clin Infect Dis. 2004 Feb
351 15;38(4):483-9. doi: 10.1086/380973. Epub 2004 Jan 28. PMID: 14765339; PMCID:
352 PMC7107942.
- 353 [14] Ghweil AA, Hassan MH, Khodeary A, Mohamed AO, Mohammed HM, Abdelazez AA,
354 et al. Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample
355 of ESNA Quarantine Hospital's Patients, Egypt: A Retrospective Study. Infect Drug
356 Resist. 2020 Jul 17; 13:2375-2383. doi: 10.2147/IDR.S263489. PMID: 32765012;
357 PMCID: PMC7381791.

- 358 [15] Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A
359 comparison with young and middle-aged patients. *J Infect.* 2020 Jun;80(6):e14-e18. doi:
360 10.1016/j.jinf.2020.03.005. Epub 2020 Mar 27. PMID: 32171866; PMCID: PMC7102640.
- 361 [16] Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. *BMJ.*
362 2020 Apr 1;369:m1327. doi: 10.1136/bmj.m1327. PMID: 32238354.
- 363 [17] Wang C, Deng R, Gou L, Fu Z, Zhang X, Shao F, et al. Preliminary study to identify
364 severe from moderate cases of COVID-19 using combined hematology parameters. *Ann*
365 *Transl Med.* 2020 May;8(9):593. doi: 10.21037/atm-20-3391. PMID: 32566620; PMCID:
366 PMC7290538.
- 367 [18] Li X, Xu Z, Wang T, Xu X, Li H, Sun Q, et al. Clinical laboratory characteristics of
368 severe patients with coronavirus disease 2019 (COVID-19): A systematic review and
369 meta-analysis. *Clin Epidemiol Glob Health.* 2021 Jan-Mar;9:184-190. doi:
370 10.1016/j.cegh.2020.08.012. Epub 2020 Sep 15. PMID: 32954048; PMCID:
371 PMC7491425.
- 372 [19] Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease
373 Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel
374 coronavirus diseases (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2020
375 Feb 10;41(2):145-151. Chinese. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. PMID:
376 32064853.
- 377 [20] Manavi KR, Alston-Mills BP, Thompson MP. History of tobacco, vitamin D and women.
378 *Int J Vitam Nutr Res.* 2020 Oct;90(5-6):389-394. doi: 10.1024/0300-9831/a000640. Epub
379 2020 Feb 24. PMID: 32091316.

- 380 [21] Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. *Clin Rev*
381 *Allergy Immunol.* 2019 Jun;56(3):308-321. doi: 10.1007/s12016-017-8648-x. PMID:
382 28963611.
- 383 [22] Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic
384 Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.
385 *Molecules.* 2020 Dec 4;25(23):5725. doi: 10.3390/molecules25235725. PMID: 33291581;
386 PMCID: PMC7731255
- 387 [23] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in
388 Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. *Arch*
389 *Acad Emerg Med.* 2020 Mar 24;8(1): e35. PMID: 32232218; PMCID: PMC7096724.
- 390 [24] Marhl M, Grubelnik V, Magdič M, Markovič R. Diabetes and metabolic syndrome as
391 risk factors for COVID-19. *Diabetes Metab Syndr.* 2020 Jul-Aug;14(4):671-677. doi:
392 10.1016/j.dsx.2020.05.013. Epub 2020 May 8. PMID: 32438331; PMCID: PMC7205616.
- 393 [25] Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat*
394 *Rev Cardiol.* 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. PMID:
395 32139904; PMCID: PMC7095524.
- 396 [26] Seys LJM, Widagdo W, Verhamme FM, Kleinjan A, Janssens W, Joos GF, et al. DPP4,
397 the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of
398 Smokers and Chronic Obstructive Pulmonary Disease Patients. *Clin Infect Dis.* 2018 Jan
399 6;66(1):45-53. doi: 10.1093/cid/cix741. PMID: 29020176; PMCID: PMC7108100.
- 400 [27] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics
401 of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy.* 2020
402 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27. PMID: 32077115.

- 403 [28] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal
404 COVID-19 cases: A systematic literature review and meta-analysis. *J Infect.* 2020
405 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23. PMID:
406 32335169; PMCID: PMC7177098.
- 407 [29] Shi L, Wang Y, Wang Y, Duan G, Yang H. Dyspnea rather than fever is a risk factor for
408 predicting mortality in patients with COVID-19. *J Infect.* 2020 Oct;81(4):647-679. doi:
409 10.1016/j.jinf.2020.05.013. Epub 2020 May 15. PMID: 32417316; PMCID:
410 PMC7228739.
- 411 [30] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. Global
412 COVID-19 Thrombosis Collaborative Group, endorsed by the ISTH, NATF, ESVM, and
413 the IUA, supported by the ESC Working Group on Pulmonary Circulation and Right
414 Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease:
415 Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-
416 Art Review. *J Am Coll Cardiol.* 2020 Jun 16;75(23):2950-2973. doi:
417 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. PMID: 32311448; PMCID:
418 PMC7164881.
- 419 [31] Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al.
420 Hypercoagulability of COVID-19 patients in intensive care unit: A report of
421 thromboelastography findings and other parameters of hemostasis. *J Thromb Haemost.*
422 2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24. PMID: 32302438.
- 423 [32] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts
424 disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target*

- 425 Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. PMID: 32296069; PMCID:
426 PMC7100419.
- 427 **[33]** Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-Inflammatory Parameters
428 in COVID-19 Cases: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*.
429 2020 Jun 9; 7:301. doi: 10.3389/fmed.2020.00301. PMID: 32582743; PMCID:
430 PMC7295898.
- 431 **[34]** Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19
432 patients in the emergency room. *Biomark Med*. 2020 Sep;14(13):1207-1215. doi:
433 10.2217/bmm-2020-0317. Epub 2020 Jul 21. PMID: 32692248; PMCID: PMC7372996.
- 434 **[35]** Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. *Ann*
435 *Hematol*. 2020 Jun;99(6):1205-1208. doi: 10.1007/s00277-020-04019-0. Epub 2020 Apr
436 15. PMID: 32296910; PMCID: PMC7156897.
- 437 **[36]** Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory
438 predictors of death from coronavirus disease 2019 (COVID-19) in the area of
439 Valcamonica, Italy. *Clin Chem Lab Med*. 2020 Jun 25;58(7):1100-1105. doi:
440 10.1515/cclm-2020-0459. PMID: 32573995.
- 441 **[37]** Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China: Guan
442 W, Ni Z, Hu Y, et al. *N Engl J Med*. 2020 Feb 28 [Online ahead of print] DOI:
443 10.1056/NEJMoa2002032. *J Emerg Med*. 2020 Apr;58(4):711–2. doi:
444 10.1016/j.jemermed.2020.04.004. Epub 2020 Jun 3. PMCID: PMC7266766.
- 445 **[38]** Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in
446 predicting the severity of COVID-19. *J Med Virol*. 2020 Oct;92(10):2188-2192. doi:
447 10.1002/jmv.26031. Epub 2020 Jun 2. PMID: 32436996; PMCID: PMC7280691.

- 448 [39] Sulejmani A, Galimberti E, Giacobone C, Milano A, Scopetta E, Intra J, et al. Baseline
449 characteristics of COVID-19 Italian patients admitted to Desio Hospital, Lombardy: a
450 retrospective study. *Scand J Clin Lab Invest.* 2021 Feb;81(1):18-23. doi:
451 10.1080/00365513.2020.1846211. Epub 2021 Jan 6. PMID: 33403882.
- 452 [40] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and
453 Treatment of Coronavirus (COVID-19). 2021 Apr 20. In: StatPearls [Internet]. Treasure
454 Island (FL): StatPearls Publishing; 2021 Jan-. PMID: 32150360.
- 455 [41] Lalueza A, Ayuso B, Arrieta E, Trujillo H, Folgueira D, Cueto C, et al; INFLUDOC
456 group. Elevation of serum ferritin levels for predicting a poor outcome in hospitalized
457 patients with influenza infection. *Clin Microbiol Infect.* 2020 Nov;26(11): 1557.e9-
458 1557.e15. doi: 10.1016/j.cmi.2020.02.018. Epub 2020 Feb 28. PMID: 32120038.
- 459 [42] Schuetz P. The Role of Procalcitonin for Risk Assessment and Treatment of COVID-19
460 Patients. *HealthManagement.* 2020;20(5):380-82.
- 461 [43] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
462 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
463 descriptive study. *Lancet.* 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-
464 6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.
- 465 [44] Lu H, Ai J, Shen Y, Li Y, Li, T, Zhou X, et al. A descriptive study of the impact of
466 diseases control and prevention on the epidemics dynamics and clinical features of SARS-
467 CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention.
468 medRxiv 2020.02.19.20025031; doi: <https://doi.org/10.1101/2020.02.19.20025031>.
469 [Online ahead of print].

- 470 [45] Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and
471 Management. *AJR Am J Roentgenol.* 2020 Jun;214(6):1280-1286. doi:
472 10.2214/AJR.20.22954. Epub 2020 Mar 4. PMID: 32130038.
- 473 [46] Hafez MAF. The mean severity score and its correlation with common computed
474 tomography chest manifestations in Egyptian patients with COVID-2019 pneumonia.
475 *Egypt J Radiol Nucl Med.* 2020;51(1):254. doi: 10.1186/s43055-020-00368-y. Epub 2020
476 Dec 8. PMCID: PMC7721816.
- 477 [47] Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 (COVID-19)
478 Pneumonia in 62 Patients in Wuhan, China. *AJR Am J Roentgenol.* 2020
479 Jun;214(6):1287-1294. doi: 10.2214/AJR.20.22975. Epub 2020 Mar 5. PMID: 32134681.
- 480 [48] Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An
481 Imaging Tool for Assessing Severe COVID-19. *Radiol Cardiothorac Imaging.* 2020 Mar
482 30;2(2): e200047. doi: 10.1148/ryct.2020200047. PMID: 33778560; PMCID:
483 PMC7233443.

484 **Table 1:** Sociodemographic characteristics and co-morbidities of all studied patients and
 485 according to COVID-19 severity and mortality.

		TOTAL N=180	SEVERITY			MORTALITY		
			Non-severe N=130	Severe N=50	p-value	Survivors N= 155	Non-survivors N= 25	P-value
Age (years)	Median (IQR)	48.0 (15-94)	43 (15-94)	60 (22-91)	0.004	45.0 (15-94)	57.0 (27-80)	0.005
Sex n., %	Male	63 (35.0%)	41 (31.5%)	22 (44.0%)	0.116	53 (34.2%)	10 (40.0%)	0.572
	Female	117 (65.0%)	89 (68.5%)	28 (56.0%)		102 (65.8%)	15 (60.0%)	
Co-morbidities n., %	Diabetes	84 (46.7%)	49 (37.7%)	35 (70.0%)	≤0.001	67 (43.2%)	17 (68.0%)	0.021
	HTN	65 (36.1%)	36 (27.7%)	29 (58.0%)	≤0.001	49 (31.6%)	16 (64.0%)	0.002
	IHD	25 (13.9%)	14 (10.8%)	11 (22.0%)	0.051	18 (11.6%)	7 (28.0%)	0.028
	Stroke	9 (5.0%)	3 (2.3%)	6 (12.0%)	0.008	4 (2.6%)	5 (20.0%)	0.003
	CKD	8(4.4%)	1 (0.8%)	7 (14.0%)	≤0.001	6 (3.9%)	2 (8.0%)	0.353
	CLD	36 (20.0%)	20 (15.4%)	16 (32.0%)	0.013	31 (20.0%)	5 (20.0%)	1.000
	COPD	60 (33.3%)	35 (26.9%)	25 (50.0%)	0.003	52 (33.5%)	8 (32.0%)	0.879

486 *CKD: chronic kidney disease; CLD, chronic liver disease; COPD: chronic obstructive*
 487 *pulmonary disease; HTN, hypertension; IHD: ischemic heart disease. Significance (P-value) was*
 488 *set at ≤0.05.*

489 **Table 2:** Clinical characteristics and outcomes of all studied patients and according to COVID-
490 19 severity and mortality.

		TOTAL	SEVERITY			MORTALITY		
			Non-severe	Severe	p-value	Survivors	Non-survivors	p-value
		N=180	N=130	N=50		N= 155	N= 25	
Symptoms n., (%)	Fatigue	163 (90.6%)	119 (91.5%)	44 (88.0%)	0.467	142 (91.6%)	21 (84.0%)	0.227
	Fever	125 (69.4%)	89 (68.5%)	36 (72.0%)	0.644	109 (70.3%)	16 (64.0%)	0.524
	Dyspnea	125 (69.4%)	88 (67.7%)	37 (74.0%)	0.411	103 (66.5%)	22 (88.0%)	0.030
	Arthralgia	133 (73.9%)	93 (71.5%)	40 (80.0%)	0.247	115 (74.2%)	18 (72.0%)	0.817
	Myalgia	135 (75.0%)	98 (75.4%)	37 (74.0%)	0.848	115 (74.2%)	20 (80.0%)	0.534
	Cough	124 (68.9%)	86 (66.2%)	38 (76.0%)	0.201	104 (67.1%)	20 (80.0%)	0.196
	Anosmia	37 (20.6%)	28 (21.5%)	9 (18.0%)	0.599	34 (21.9%)	3 (12.0%)	0.254
	Rhinitis	18 (10.0%)	16 (12.3%)	2 (4.0%)	0.096	17 (11.0%)	1 (4.0%)	0.281
	Headache	65 (36.1%)	46 (35.4%)	19 (38.0%)	0.744	55 (35.5%)	10 (40.0%)	0.663
	Chest tightness	71 (39.4%)	50 (38.5%)	21 (42.0%)	0.664	57 (36.8%)	14 (56.0%)	0.068
	Sore throat	26 (14.4%)	19 (14.6%)	7 (14.0%)	0.916	23 (14.8%)	3 (12.0%)	0.708
	Nausea	22 (12.2%)	18 (13.8%)	4 (8.0%)	0.283	20 (12.9%)	2 (8.0%)	0.487
	Diarrhea	20 (11.1%)	16 (12.3%)	4 (8.0%)	0.410	19 (12.3%)	1 (4.0%)	0.223
	Loss of taste	12 (6.7%)	11 (8.5%)	1 (20.0%)	0.120	11 (7.1%)	1 (4.0%)	0.565
	Thrombosis	48 (26.7%)	29 (22.3%)	19 (38.0%)	0.030	39 (25.2%)	9 (36.0%)	0.255
CT-SS	Median (IQR)	16.5 (0-24)	15 (0-24)	21 (5-23)	≤0.001	7 (0-23)	20 (0-24)	≤0.001
ICU admission	n., (%)	55 (30.6%)	7 (5.4%)	48 (96.0%)	≤0.001	35 (22.6%)	20 (80.0%)	≤0.001
Hospital stay (days)	Median (IQR)	14 (3-29)	10 (3-22)	22 (10-29)	≤0.001	12 (3-29)	22 (3-29)	0.001
In-hospital mortality n., (%)	Discharged alive	155 (86.1%)	121 (93.1%)	34 (68.0%)	≤0.001			
	Died	25 (13.9%)	9 (6.9%)	16 (32.0%)	≤0.001			

CT-SS: CT-scoring system. Significance (P-value) was set at ≤0.05.

491

492 **Table 3:** Baseline laboratory findings of all studied patients and according to COVID-19
 493 severity and mortality.

	TOTAL	SEVERITY			MORTALITY		p-value
		Non-severe	Severe	p-value	Survivors	Non-survivors	
	n=180	n=130	n=50		n= 155	n= 25	
TLC ($\times 10^3/\mu\text{l}$)	7.6 (0.1-79.0)	7.5 (1.2-79.0)	7.9 (0.1-24.0)	0.856	7.6 (0.1-79.0)	7.6 (1.2-21.6)	0.849
NL ($\times 10^3/\mu\text{l}$)	2.5 (0.9-5.8)	1.9 (0.9-4.2)	2.9 (0.9-5.8)	≤ 0.001	2.1 (0.9-4.2)	2.6 (0.9-5.8)	0.001
LYMPH ($\times 10^3/\mu\text{l}$)	1.2 (0.0-6.0)	1.5 (0.1-6.6)	0.9 (.0-3.6)	≤ 0.001	1.3 (0.0-6.6)	1.1 (0.1-2.4)	0.005
HB (gm/dl)	11.4 (2.9-16.7)	11.5(5.0-16.7)	10.5 (2.9-15.0)	0.280	11.2 (2.9-16.7)	12.4 (6.6-15.2)	0.104
PLT ($\times 10^3/\mu\text{l}$)	251.5 (6-716)	254.0 (6-716)	240.0 (11-650)	0.627	256.0 (6-716)	208.0 (6-485)	0.124
Ferritin (ng/mL)	371.5 (16-4947)	215.5 (16-2273)	860.5 (130-4947)	≤ 0.001	342.0(16-4947)	878 (130-2577)	≤ 0.001
PCT (ng/mL)	0.9 (0-5.9)	0.8 (0.0-5.1)	2.8 (0.4-5.9)	≤ 0.001	0.9 (.0-5.9)	2.5 (0.6-5.9)	≤ 0.001
ESR (mm/h)	70.0 (12-210)	57.0 (12-140)	110.0 (49-210)	≤ 0.001	65.0 (12-187)	110 (30-210)	≤ 0.001
CRP (mg/L)	48.0 (6.0-378.0)	29.5 (6.0-372.0)	102.5 (11-378.0)	≤ 0.001	45.0 (6.0-378)	91 (10-304)	0.007
D-dimer (mg/L)	1.1 (0.1-12.5)	0.8 (0.1-12.5)	2.5 (0.7-12.2)	≤ 0.001	0.9 (0.1-9.5)	3.4 (0.6-12.5)	≤ 0.001
LDH (IU/L)	222.0 (18-1889)	189.0 (18-1889)	392.0 (46-1121)	≤ 0.001	207 (18-1889)	388 (123 -1091)	0.002
AST (IU/L)	26.0 (2-2044)	25.0 (11-2044)	45.0 (2-898)	0.018	25 (2-2044)	45 (12-898)	0.002
ALT (IU/L)	30.0 (10-1344)	25.0 (10-1344)	45.0 (10-511)	≤ 0.001	27 (10-1344)	45 (18-511)	0.001

494 *ALT: Alanine amino transferase; AST: Aspartate aminotransferase; CRP: C-reactive protein;*
 495 *ESR: Erythrocyte sedimentation rate; HB: Hemoglobin; LDH: Lactate dehydrogenase; Lymph:*
 496 *Lymphocytes; PCT: Procalcitonin; PLT: Platelets; NL: Neutrophils; TLC: Total leukocytic*
 497 *count. Data presented as median (IQR). Significance (P-value) was set at ≤ 0.05 .*

498 **Table 4:** Multivariate logistic regression analysis of risk factors associated with COVID-19
 499 severity and in-hospital mortality.

Variables	SEVERITY				
	B	S.E.	P-value	Odds ratio	95% CI
Diabetes	1.082	0.518	0.037	2.951	1.070-8.137
COPD	1.192	0.516	0.021	3.294	1.199-9.053
CT-SS (≥ 17)	1.416	0.673	≤ 0.001	1.205	1.089-1.334
Ferritin (≥ 350 ng/mL)	2.405	0.702	0.001	11.08	2.796-41.551
AST (≥ 40 IU/L)	1.124	0.487	0.021	3.07	1.842-7.991
Lymphocytes ($< 1 \times 10^3/\mu\text{L}$)	1.387	0.448	0.005	4.002	1.537-10.421
MORTALITY					
Dyspnea	1.388	0.686	0.043	4.006	1.045-15.359
CT-SS (≥ 17)	2.023	0.792	0.002	1.271	1.091-1.482
AST (≥ 40 IU/L)	1.061	0.497	0.033	2.89	1.091-7.661

500 *AST: Aspartate aminotransferase; COPD: Chronic obstructive pulmonary disease; CT-SS: CT-*
 501 *scoring system. Significance (P-value) was set at ≤ 0.05 .*